purity testing is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Assessment of kidney function occurs in different ways, using the presence of symptoms and signs, as well as measurements using urine tests, blood tests, and medical imaging. Functions of a healthy kidney include maintaining a person's fluid balance, maintaining an acid-base balance; regulating sodium and other electrolytes; clearing toxins; regulating blood pressure; and regulating hormones, such as erythropoietin; and activation of vitamin D. The kidney is also involved in maintaining blood pH balance.
Romanowsky was the first to realise the differences in the staining abilities of eosin and methylene blue. The individual stains (monochromatic staining) were good only for general colouring of tissue or cell, but not for contrasting the different components. By mixing specific amount of eosin and methylene blue, Romanowsky found that the mixture gave images of contrasting clarity that helped to visualise different parts and components of cells. This mixture method, polychromatic staining or polychromy, with various modifications became the most efficient way of staining cells for identifying cellular components. The chemical phenomenon by which a mixture of stains produces vibrant cell images is known as "Romanowsky effect". In December 1890, Romanowsky published his invention as a preliminary report of his major work for his doctoral thesis in the journal Vrach as "On the question of the structure of malaria parasites" (as translated in English). Incorrectly, it is more often recorded in books and journals that Romanowsky published his findings in 1891, which led to a controversy on priority that Ernst Malachowsky independently developed the technique as the latter published his research in August 1891.
In 1996, the US had about 2 deaths per 10,000 motor vehicles, compared to 1.9 in Germany, 2.6 in France, and 1.5 in the UK. In 1998, there were 3,421 fatal crashes in the UK, the fewest since 1926; in 2010, this number was further reduced to 1,857 and was attributed to the 2009–2010 scrappage scheme. The sizable traffic safety lead enjoyed by the US since the 1960s had narrowed significantly by 2002, with the US improvement percentages lagging in 16th place behind those of Australia, Austria, Canada, Denmark, Finland, Germany, United Kingdom, Iceland, Japan, Luxembourg, the Netherlands, New Zealand, Norway, Sweden, and Switzerland in terms of deaths per thousand vehicles, while in terms of deaths per 100 million vehicle miles travelled, the US had dropped from first place to tenth place. Transportation safety in the United States is monitored by various agencies.
The essential replication system in RK2 consists of an origin of replication, oriV, and a gene, trfA, whose gene product, the TrfA protein, binds to and activates oriV. In Escherichia coli, replication proceeds unidirectionally from oriV after activation by TrfA. In E. coli, multiple plasmid copies appear to cluster together, creating a few multiplasmid clusters in each cell. The copy number of RK2 is about 4-7 per cell in E. coli and 3 in P. aeruginosa.
1.4 Alternatively some books provide the following formula and is called Reticulocyte Index (RI): Whereas normal reticulocytes lose their RNA within 24 hours, a severely anemic patient with a full erythropoietin response will release reticulocytes that take from 2-3 days to lose their RNA. This has the effect of raising the reticulocyte count simply because reticulocytes produced on any single day will spend more than 1 day in circulation as reticulocytes and, therefore, will be counted for 2 or more days. The simplest method for correcting the reticulocyte count, to obtain a more accurate daily production index, is to divide the corrected count by a factor of 2 (or multiply with ½) whenever polychromasia (the presence of immature marrow reticulocytes or "shift" cells) is observed on the smear or the immature fraction on the automated counter is increased. R I = R e t i c P e r c e n t a g e ∗ H e m a t o c r i t N o r m a l H e m a t o c r i t ∗ 0.5 {\displaystyle RI=ReticPercentage*{Hematocrit \over NormalHematocrit}*0.5} → R I = 5 ∗ 25 45 ∗ 0.5 =
Sources: en.wikipedia.org
The Green Chemistry Institute (GCI) supports the "implementation of green chemistry and engineering throughout the global chemistry enterprise." The GCI organizes an annual conference, the Green Chemistry and Engineering Conference, provides research grants, administers awards, and provides information and support for green chemistry practices to educators, researchers, and industry. The GCI was founded in 1997 as an independent non-profit organization, by chemists Joe Breen and Dennis Hjeresen in cooperation with the Environmental Protection Agency. In 2001, the GCI became a part of the American Chemical Society.[1]
The peptide-mRNA:cDNA fusions can be selected over immobilized selection targets for several rounds (Figure 3). There might be a relatively high background for the first few rounds of selection, and this can be minimized by increasing selection stringency, such as adjusting salt concentration, amount of detergent, and/or temperature during the target/fusion binding period. Following binding selection, those library members that stay bound to the immobilized target are PCR amplified. The PCR amplification step will enrich the population from the mRNA-display library that has higher affinity for the immobilized target. Error-prone PCR can also be done in between each round of selection to further increase the diversity of the mRNA-display library and reduce background in selection. A less time-consuming protocol for mRNA display was recently published.
Aspartate transaminase, as with all transaminases, operates via dual substrate recognition; that is, it is able to recognize and selectively bind two amino acids (Asp and Glu) with different side-chains. In either case, the transaminase reaction consists of two similar half-reactions that constitute what is referred to as a ping-pong mechanism. In the first half-reaction, amino acid 1 (e.g., L-Asp) reacts with the enzyme-PLP complex to generate ketoacid 1 (oxaloacetate) and the modified enzyme-PMP. In the second half-reaction, ketoacid 2 (α-ketoglutarate) reacts with enzyme-PMP to produce amino acid 2 (L-Glu), regenerating the original enzyme-PLP in the process. Formation of a racemic product (D-Glu) is very rare. The specific steps for the half-reaction of enzyme-PLP + aspartate ⇌ {\displaystyle \rightleftharpoons } enzyme-PMP + oxaloacetate are as follows (see figure); the other half-reaction (not shown) proceeds in the reverse manner, with α-ketoglutarate as the substrate.
The binding of S-arrestin to rhodopsin is specific and involves changes that occur in rhodopsin after activation. Important serine (Ser) and threonine (Thr) residues in rhodopsin's tail, particularly Thr-340 and Ser-343, are phosphorylated by enzymes called GRKs. These phosphorylated residues strongly attract S-arrestin, helping it bind tightly and effectively shut down rhodopsin's signaling. Additionally, studies of the protein structure have shown that during activation, rhodopsin's transmembrane helix 7 (TM7) and helix 8 change shape. These changes expose a binding site that interacts with a specific part of arrestin called the "finger loop." This interaction, clearly seen in the crystal structure (PDB ID: 4ZWJ), shows how arrestin fits precisely onto activated and phosphorylated rhodopsin, efficiently stopping the visual signal. Arrestin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
12(S)-HpETE and 12(S)-HETE induce itching responses when injected into the skin of mice; this has led to the suggestion that these metabolites contribute to the itching (i.e. clinical pruritus) which accompanies such conditions as atopic dermatitis, contact dermatitis, urticaria, chronic renal failure, and cholestasis. Since it mediates 12(S)-HETE-induced itching in the mouse model, BLT2 rather than GPR31 may mediate human itch in these reactions.
Evolutionary biology is a subfield of biology that analyzes the mechanisms of evolution. Evolution accounts for the unity and diversity of life on Earth; Theodosius Dobzhansky famously said "nothing in biology makes sense except in the light of evolution". Population genetics for example studies how genetic variation develops, how it is inherited, and how the evolutionary mechanisms shape a population's genetic composition. Research in evolutionary biology covers many topics and incorporates ideas from diverse areas, such as molecular genetics and mathematical and theoretical biology. Some fields of evolutionary research try to explain phenomena that were poorly accounted for in the modern evolutionary synthesis. These include speciation, the evolution of sexual reproduction, the evolution of cooperation, the evolution of ageing, and evolvability. Ecology is the study of the distribution and abundance of life, the interaction between organisms and their environment.
Plant breeding started with sedentary agriculture and particularly the domestication of the first agricultural plants, a practice which is estimated to date back 9,000 to 11,000 years. Initially early farmers simply selected food plants with particular desirable characteristics, and employed these as progenitors for subsequent generations, resulting in an accumulation of valuable traits over time. Grafting technology had been practiced in China before 2000 BCE. By 500 BCE grafting was well established and practiced. Gregor Mendel (1822–84) is considered the "father of genetics". His experiments with plant hybridization led to his establishing laws of inheritance. Genetics stimulated research to improve crop production through plant breeding. Selective breeding played a crucial role in the Green Revolution of the 20th century. Modern plant breeding is applied genetics, but its scientific basis is broader, covering molecular biology, cytology, systematics, physiology, pathology, entomology, chemistry, and statistics (biometrics). It has also developed its own technology.
TP0586532 is an experimental antibiotic drug, which acts as a potent and selective inhibitor of the bacterial enzyme UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC). This enzyme is important for the production of Lipid A, a key component of the cell membrane of Gram-negative bacteria. Previous inhibitors of LpxC have failed to progress into clinical trials in humans, mostly because of off-target cardiovascular toxicity, so TP0586532 was based on a different structural class which is hoped to reduce this risk. In animal studies it shows activity against carbapenem-resistant Klebsiella pneumoniae but has not yet progressed into human trials. LPC-233
Vehicle inspection is a procedure mandated by national or subnational governments in many countries, in which a vehicle is inspected to ensure that it conforms to regulations governing safety, emissions, or both. Inspection can be required at various times, e.g., periodically or on the transfer of title to a vehicle. If required periodically, it might be termed periodic motor vehicle inspection, or MOT test in the UK, or roadworthiness test in EU directives. Typical intervals are every two years (in EU) and every year (in UK). When a vehicle passes inspection, often a sticker is placed on the vehicle's windshield or registration plate to simplify later controls, but in some countries (such as Netherlands since 1994) this is no longer necessary. Vehicles are tested at inspection stations when due for inspection. Most US inspection decals/stickers display the month's number and the year. They are called testing centre in EU directives. Vehicle inspection exists in the United States. In Victoria, Australia, safety features checked include the structure of the vehicle, the tires (depth of tread), the wheels, the engine, steering, suspension, brakes, and lights and seatbelts.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.